Stock Taper 
OKYO Pharma Limited, a UK-based preclinical biopharmaceutical company founded in 2007, develops therapeutics like OK-101 for dry eye and OK-201 for neuropathic ocular pain.
Urcosimod, OKYO Pharma's lead drug candidate in Phase 2 for neuropathic corneal pain and dry eye disease, has FDA Fast Track designation, highlighting its potential to treat inflammatory eye conditions.
OKYO Pharma announced positive top-line data from its Phase 2 clinical trial of urcosimod for the treatment of neuropathic corneal pain (NCP) on July 16, 2025. This was a significant milestone as OKYO is the first company to conduct a clinical study for NCP, a severe condition with no FDA-approved therapies. The positive results generated considerable media attention and investor interest due to the drug's potential to address a major unmet medical need.
OKYO Pharma announced the appointment of Robert J. Dempsey as its new Chief Executive Officer, effective January 5, 2026. This move is designed to leverage Dempsey's extensive experience in global ophthalmology drug development and commercialization to guide the company's lead candidate, urcosimod, through upcoming clinical trials. Former CEO Gary S. Jacob will transition to the role of Chief Development Officer to ensure continuity.
LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
 IMMX | $10.15 | COMPARE |
 SLGL | $76.33 | COMPARE |
 MGNX | $3.74 | COMPARE |
 WHWK | $3.71 | COMPARE |
 ZNTL | $2.81 | COMPARE |
 COYA | $4.92 | COMPARE |
 TLSA | $1.11 | COMPARE |
 PLRX | $1.04 | COMPARE |
